Barclays lowered the firm’s price target on Novo Nordisk (NVO) to DKK 360 from DKK 375 and keeps an Equal Weight rating on the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk’s U.S. public affairs boss exits company, Reuters reports
- Midday Fly By: U.S. oil majors rise on Venezuela news, Versant completes spinoff
- Eli Lilly Stock (LLY) Falls 4% as Rival Novo Nordisk Begins Selling Obesity Pill in U.S.
- Hims & Hers again left off Novo partner list, says Citi
- LifeMD expands collaboration with Novo Nordisk for Wegovy pill